Description

CJC-1295 with DAC (Drug Affinity Complex) is a research-use-only synthetic peptide analog of endogenous growth hormone-releasing hormone (GHRH). The inclusion of the Drug Affinity Complex (DAC) allows the peptide to covalently bind to circulating albumin post-administration, significantly extending its half-life and preventing rapid enzymatic degradation. In laboratory environments, it is widely utilized to investigate the mechanics of continuous, non-pulsatile stimulation of pituitary somatotroph cells, resulting in a sustained elevation of baseline growth hormone (GH) and downstream insulin-like growth factor 1 (IGF-1) levels over an extended tracking period. It is intended strictly for laboratory research and should not be used for human consumption, medical treatment, or diagnostic purposes.

Research Reference Amounts 1 mg — 2 mg

Research Titration Reference Due to the extended pharmacokinetic profile provided by the DAC modification, these reference amounts are commonly evaluated on a weekly administration schedule, depending on the specific longitudinal assay metrics and laboratory protocols.

LABORATORY NOTICE: All products listed are for IN VITRO LABORATORY RESEARCH ONLY. They are not for human or veterinary use. Any research conducted must be performed by qualified professionals in a controlled environment.